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Abstract/Resume
Disruption ofthe growth hormone/insulin-like growth factor-1 (GH/IGF-I) axis has been
reported and studied in menopause, hypothalamic amenorrhea, and anorexia nervosa, but
not in weight-stable amenorrheic athletes. We investigated the effects of short-term
transdermal estradiol on basal and exercise-stimulated serum GH, IGF-1, and associated
binding proteins (IGFBP-1 andIGFBP-3) in seven weight-stable female amenorrheic ath-
letes with percentage body fats greater that 12%. Each subject received a 72h placebo
patch followed by 144h of transdermal estradiol. Serum samples for GH, IGF-1, IGFBP-1,
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and IGFBP-3 were obtained at baseline (tl), 72hr (t2), 144hr (t3), and during three 90-
minute trials of aerobic exercise. Basal, and exercise GH, IGF-1, and IGFBP-1 were not
different between trials. Baseline IGFBP-3 decreased from tl to t2 (p = 0.04) and serum
free fatty acids increased from tl to t2, and tl to t3 (p = 0.04, and 0.02 respectively). These
findings differ from postmenopausal women, and women having weightloss-associated
amenorrhea, suggesting that estrogen, exercise, and nutritional deficiencies may have in-
dependent effects on the GH/IGF-1 axis.
Le deriglement de I'axe hormone de croissance facteur de croissance de type insuline-1
(GH/IGF-1) a ete observe et etudie chez les femmes menopausees, les femmes souffrant
d'amenorrhee hypothalamique et d'anorexie mentale, mais non chez les athletes en
amenorrhee et de masse corporelle stable. Nous avons etudie les effets a court terme de
I'aestradiol transdermique sur les niveaux seriques de base et a I'effort de GH, IGF-1, et
des proteines de liaison associees (IGFBP-1 et IGFBP-3) chez sept athl&tes feminines en
amenorrhee, de masse corporelle stable et dont le pourcentage de gras est plus de 12 %.
Tous les sujets se sont appliques un timbre temoin durant 72 h puis un timbre d'aestradiol
durant 144 h. Les concentrations seriques de GH, IGF-1, IGFBP-1 et IGFBP-3 ont ete
mesurees a tl (base), t2 (72 h) et t3 (144 h) et au cours de trois epreuves aerobies d'une
duree de 90 min. Les concentrations seriques de GH, IGF-1, IGFBP-1 furent les mimes d.
I'effort qu'au repos. Le niveau de base de IGFBP-3 a diminue de tl a t2 (p = 0,04) et le
niveau serique des acides gras libres a augmente de tl a t2 et de tl at3 (p = 0,04, et 0,02,
respectivement). Ces observations different de celles observees chez les femmes menopausees
et chez les femmes en amenorrhee ayant perdu du poids, ce qui signifie probablement que
les cestrogenes, l'exercice et les carences alimentaires ont des effets independants sur I'axe
GH/IGF-1.
Introduction
Various biological conditions such as aging, starvation, sex steroid deficiencies,
and obesity, appear to affect the secretion of growth hormone (GH), insulin-like
growth factor-1 (IGF-1) and the associated binding proteins. Insulin-like growth
factor (IGF) binding proteins serve as carriers of IGF in the circulation, prolong
the half-life ofthe IGF's, and act as regulators ofthe biological actions by regulat-
ing the availability of IGF's to their cell surface receptors (Koistinen et al., 1996).
Estrogen is one important mediator of GH secretion, and the effect of endogenous,
oral and transdermal estrogen on the GH/IGF-1 axis has been investigated during
aging, menopause, and weightloss-associated amenorrhea (Bellantoni et al., 1996;
Cano et al., 1999; Genazzani et al., 1998).
In human studies designed to assess the effects of estrogen on the GH/IGF-1
axis, two variables appear to be critical; namely the etiology of the estrogen defi-
ciency, and the route of estrogen administration (oral vs. transdermal). The bio-
logical effects of estrogen replacement have been primarily studied in post-meno-
pausal women or in younger women experiencing hypothalamic amenorrhea sec-
ondary to weight loss or anorexia nervosa (Bellantoni et al., 1996; Genazzani et
al., 1993; O'SuUivan et al., 1998). Weightloss-associated hypothalamic amenor-
rhea is characterized by decreased percentage of body fat, nutritional deficiencies,
and low insuUn and leptin concentrations aU of which may independently infiu-
ence GH and IGF-1 concentrations (De Cree, 1998; LaughUn et al., 1998; Yen and
66 • Waters, Dorin, Quails, et al.
LaughUn, 1996). An altemative model of amenorrhea is the syndrome of athletic
amenorrhea. Although women with athletic and weightloss-associated hypotha-
lamic amenorrhea share several features, they differ importantly in several param-
eters (LaughUn et al., 1998; Yen, 1993; Yen and Laughlin, 1996). For example,
women with a severe form of weight loss (anorexia nervosa) demonstrate hyperc-
holesterolemia, decreased 3,5,3'-Triiodothyronine (Tj) and reverse T3 all which
coexist with psychological impairments (De Cree, 1998). Conversely, amenor-
rheic athletes without weight loss or eating disorders do not exhibit these meta-
boUc anomalies, but do demonstrate alterations in the GH/IGF-1 axis (Waters et
al., 2001).
To our knowledge, the effect of short-term transdermal estradiol supplemen-
tation on the GH/IGF-1 axis has not been investigated in weight-stable amenor-
rheic athletes. Thus, the present study is designed to detennine if short-term,
transdermal estradiol replacement alters baseUne and exercise stimulated semm
GH and IGFBP-1 concentrations, resting measures of semm IGF-1 and associated
binding proteins or other metabolic parameters in young adult women with amen-
orrhea and estrogen deficiency due to athletic training.
Materials and Methods
SUBJECTS
Seven female athletes diagnosed with hypoestrogenemic athletic amenorrhea signed
informed consent, which was approved by the University of New Mexico Human
Research Review Committee.
A University of New Mexico outpatient General Clinical Research Center
(GCRC) appointment was scheduled and each subject completed a medical health
history, exercise habits questionnaire and eating attitudes test (Gamer et al., 1982).
Nutritional habits were further discussed with a registered dietician from the GCRC
in a personal interview. Following this preliminary screening, subjects were sched-
uled for a complete physical examination, which included basal blood sampling.
The classification of athletic amenorrhea was based on the features brought
forth by Loucks and Horvath (1985), and was defined as the absence of menstma-
tion for no less than three consecutive months prior to testing with sustained
hypoestrogenemia during a 3-week baseline testing period (3-week mean semm
estrogen level less than 75 pmol 'L"'). Presence of chronic anovulation during the
menstmal cycle was confirmed by basal progesterone (P )̂ levels less than 12 nmol
L"', and a lack in the biphasic elevation in basal body temperature over 30 days.
All subjects were currently involved in a regular training regimen and de-
scribed their average daily exercise routine as approximately 2 hours of aerobic
exercise per day (Table 1). The seven females in this study were comprised of four
recreational mnners, one recreational triathlete, one competitive mnner/cyclist,
and one collegiate heptathlete. Subjects were in good health and were required to
have body fat greater than 12%, but less than 23% (measured by Dual Energy X-
ray Absorptiometry), and a measured VO^ max exceeding 40 ml • kg"' • min"'.
Although seven amenorrheic athletes completed the study, only partial data
was available for one subject due to sampling difficulties. Sample sizes per out-
come measure are presented in the tables and figures.
Estradiol Effects • 67
Table 1 Physical Characteristics and Demographic Data of Baseline
Variable
Age (years)
Age at menarche (years)
Duration of amenorrhea (months)
Body weight (kg)
Body fat (%)
Years training
Exercise (average min • day"')
VOj^^ (ml • kg"' • min"')
Estradiol (pm • L"')
P4 nmol • L"' (single sample)
GH pmol • L"' (baseline)
IGF-1 ((JLg • L"')
IGFBP-3 ((Xg • L"')
IGFBP-1 ((xg • ml"')
Amenorrheics
(« = 7)
26.8 ± 5
12.9 ± 1
9.9 ± 6
57.4 ± 7
15.0 ± 3
6.9 ± 4
132.9 ± 71
47.0 ± 7
140.9 ± 34.5
0.95 ± 0.3
144.2 ± 69.8
293 ± 88
3.9 ± 0.4
58.4 ± 21.2
Eumenorrheics
(n = 5)
27.8 ± 4
13.0 ± 2
N/A
58.3 ± 5
24.4 ± 4*
10.4 ± 5*
120.7 ± 40
52.1 ± 2*
284.1 ± 59.*
17.2 ± 1.9*
41.9 ± 32.6*
278.4 ± 43
4.1 ± 0.5
60.8 ± 22.6
Note. Data are expressed as mean ± SD. Basal hormone values are for eumenorrheic females
from a previous study (Waters, 2001) who were matched for age and current training
regiment with the amenorrheic females in this study. P4 = progesterone, GH = growth
hormone, IGF-1 = insulin-like growth factor-1, IGFBP-3 = insulin-like growth factor binding
protein-3, IGFBP-1 = insulin-like growth factor binding protein-1. *Significant difference
by Student's / test between groups, p < .05.
Data from five eumenorrheic athletes who were recmited in a previous study
(Waters et al., 2001), and who matched the amenorrheic athletes for age and cur-
rent exercise regimen were utiUzed for baseUne (pre-treatment) hormonal and de-
mographic comparisons only. For these subjects, basal progesterone samples were
collected during the midluteal phase of the menstmal cycle. All other hormones
were collected in the early follicular phase of the menstmal cycle.
ADMINISTRATION OF THE TRANSDERMAL PLACEBO AND ESTROGEN PATCH
Subjects underwent three treatments in a single-bUnded, nonrandomized treatment
order: a) 72-hour placebo control (tl); b) 72-hour estradiol transdermal replace-
ment (2 X 0.05 mg patches, Estraderm® Ciba-Geigy), (t2) and; c) an additional 72-
hour estradiol transdermal replacement (2 x 0.05 mg patches, Estraderm® Ciba-
Geigy), (t3). To Umit the possibility of a carry-over effect on circulating blood
estradiol concentrations, the placebo trial always preceded the estrogen replace-
ment trials.
Non-medicated patches were placed on the skin of the upper buttock region
for a period of 72h after which the initial endurance exercise trial proceeded (tl).
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Figure 1. Pre-treatment screening and baseline evaluation (A), and placebo and
transdermal estradiol trials timeUne (B) for the seven subjects.
FoUowing the initial exercise trial, the placebo transdermal patches were removed
and replaced with an identical looking pair of estradiol (E2) medicated patches.
The estradiol transdermal patches provided a total dose of O.lmg estradiol every
24 hours to elicit a mid-late folUcular stage estradiol concentration (74.9-149.9 pg
ml"'). After wearing the medicated patches for 72h, the endurance exercise was
repeated (t2). Upon completion of the exercise trial, the medicated patches were
removed and replaced with a pair of new medicated patches. The subjects per-
formed a third exercise trial after an additional 72h of transdermal E2 replacement
(t3). Details ofthe study design are presented in Figure 1.
SXJB-MAXIMAL ENDURANCE EXERCISE TRIAL
Prior to the placement ofthe control placebo patch, each subject underwent a modi-
fied incremental exercise test on a treadmill to measure VO^ max. Expired air
samples were collected at 20s intervals during each trial, and analyzed (Jaeger̂ ™
Ergo-oxyscreen Cardiopulmonary System). Criterion for VO^max was a plateau
in the VO^ and Respiratory Exchange Ratio (RER) greater than 1.1. Heart rate was
determined by electrocardiography during the last 10 seconds ofeaeh work stage.
Prior to each of the three exercise trials, the subjects were hospitalized ovemight
to control for activity and food intake. Subjects consumed identical pre-testing
meal for each trial and dietary recall data were analyzed during the 72h prior to
each exercise trial. From 2100-0600h the subjects fasted but were allowed caf-
feine-free beverages. At 0600h following the ovemight hospital admission, a cath-
eter was placed in the antecubital vein and kept patent by a lOcc • h"'continuous
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drip of 0.45% half-normal saline. Fasting baseUne blood samples were obtained at
the GCRC prior to the subject being transported to the Center for Exercise and
AppUed Human Physiology (CEAHP). The subjects were transported to the CEAHP
and subsequently rested in a supine position for 2 hours. The exercise trial began
at 0800h and consisted of 90 minutes treadmill mnning at 65% VO^ max. Sample
collection times were as follows: semm GH: 0, 15, 30, 45, 60, 75, and 90nun.
Semm estradiol and semm IGFBP-1: 0,45, and 90 min. Basal semm GH, IGF-1,
IGFBP-3, estradiol, insulin, glucose and free fatty acid blood samples were ob-
tained at tl , t2, and t3 prior to the exercise tests.
MEASUREMENTS
Basal blood samples for GH, IGF-1, IGFBP-1, IGFBP-3, insuUn, free fatty acids
and glucose were obtained at the GCRC in the morning following a 12-hour fast,
and prior to transport to the CEAHP laboratory. Blood sampling during the sub-
maximal exercise trials occurred at intervals as depicted in Figure 1. Due to the
reportedly slow rates of change in IGFBP-3 and IGF-1 concentrations (De Leo et
al., 1993), these hormones were sampled at baseUne only in each trial.
Upon obtaining each blood sample, whole blood samples for GH, IGF-1,
IGFBP-1, IGFBP-3, estradiol, free fatty acids, insulin and glucose were centri-
fuged at 3000 RPM at 4 °C. Semm was dien drawn off and frozen at -70 °C for
subsequent analysis.
Semm GH and estradiol samples were analyzed using a double-antibody
method (Diagnostic Products Corp., Los Angeles, CA). Intra- and inter- assay vari-
ability for GH was 2.8% and 5.3% respectively with 0.2 ng • ml"' sensitivity. Intra-
and inter- assay variability for estradiol was 7.0% and 8.1% respectively with 7.9
pg • ml"' sensitivity. Semm IGF-1 was analyzed using the RIA acid-ETOH extrac-
tion method (Nichols Institute Diagnostics, San Juan Capistrano, CA). Sensitivity
was 0.06 |xg • L"'. Intra- and inter-assay variabiUty for IGF-1 was 2.4% and 5.2%
respectively. Semm IGFBP-3 was analyzed using RIA (Nichols Institute Diagnos-
tics, San Juan Capistrano, CA). Sensitivity was 0.06 |xg • ml"' with intra- and inter-
assay variabiUty of 3.8% and 6.3%, respectively. Semm IGFBP-1 was analyzed
using IRMA (Diagnostic Systems Laboratories. Webster, Texas). Sensitivity was
0.33 (xg • L"' with intra and inter-assay variability of 6.0% and 4.6%, respectively.
Glucose was analyzed using enzymatic spectrophotometric methods (Beckman
liquid-stat mn on Roche Cobas Bio). InsuUn was assayed using double antibody
RIA without extraction (Diagnostic Products Corp., Los Angeles CA).
STATISTICS
Baseline and peak concentrations, area under the curve for exercise semm GH,
estradiol, and IGFBP-1 were computed for each exercise trial and analyzed among
the three trials using repeated measures (RM) ANOVA. If the overall RM ANOVA
gave a significant result, then changes in baseUne insuUn, glucose, free fatty acids,
semm IGF-1, semm IGFBP-3 were analyzed using paired Student's t-test as post-
hoc tests to the RM ANOVA. Pearson correlation coefficient was utilized for cor-
relation analysis. Significance was set atp < .05 and aU analyses were performed
using Statistical Analysis System (SAS Institute, Carry, NC/STAT, 1990).
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SUBJECTS
Results
The subjects' physical and demographic characteristics are presented in Table 1.
Compared to previous data from five eumenorrheic controls, semm estradiol and
progesterone levels were significantly lower in the amenorrheic subjects, and rest-
ing GH was significantly increased (both, p < .05). BaseUne semm IGF-1 and
semm binding proteins were not significantly different between the amenorrheic
subjects and the data from the eumenorrheic controls. These hormones were also
within normal ranges reported for these assays for both the amenorrheic subjects
and eumenorrheic control data.
ESTRADIOL
Baseline estradiol concentrations were significantly higher at t2 and t3 compared
to tl (tl: 128.5 ± 16.9, t2:255.1 +27.9; t3:268.3 ±43.7 pmol-L"',/7 = 0.01). There
were no significant differences in baseUne estradiol concentrations between the t2
and t3.
Exercise estradiol concentrations at 45 and 90 minutes of exercise were sig-
nificantly increased from baseUne (p = 0.02) with the highest estradiol concentra-
tion achieved at 90 minutes during the t3 trial (Figure 2).
• tl t3
Figure 2. Estradiol response following 72 and 144 hours of transdermal estradiol
supplementation and during 90 minutes exercise at 65% VOj max. Baseline estradiol sig-
nificantly increased in response to transdermal estradiol supplementation and signifi-
cantly increased in response to exercise. There were no differences at any time point be-
tween the t2 and t3 trials, tl = placebo control trial, t2 = 72 hours estradiol, t3 = 144
hours estradiol. * p < .01 tl vs t2, f = /? < .01 tl vs t3. Data expressed as means + SEM.
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Figure 3. Growth hormone response to 90 minutes of exercise at 65% VOj max, follow-
ing 72 and 144 hours of transdermal estradiol supplementation. Diamond (tl) = 72 hours
of placebo. Square (t2) =72 hours estradiol supplementation. Triangle (t3) = 144 hours es-
tradiol supplementation. Growth hormone significantly increased in response to exercise
at 15 minutes (p < .05). There were no significant differences between the trials.
GROWTH HORMONE (GH)
There were no significant differences between the tl, t2 or t3 trials for baseUne
semm GH concentration, peak GH, or GH area under the curve (AUC).
Mean GH concentrations for aU three-exercise trials, increased significantly
from baseline (120.9 ± 69.8 pmol • L"') to a peak at approximately 15 minutes
(562.7 + 227.9 pmol • Lr\p = 0.03, Figure 3). Although peak semm GH concentra-
tions were not different between trials, the apparent "fiattening" of the curve at t2,
was attributable to a delayed time to peak GH in two subjects during this trial. This
delay to peak was not present in t3.
IGF-1, IGFBP-3, AND IGFBP-1
Baseline semm IGF-1 and IGFBP-1 were not significantly different between tri-
als. Baseline semm IGFBP-3 concentrations modestly, but significantly, decreased
at t2 (3.69 ± 0.48 vs 3.36 ± 0.39 |xg • L"', p = .05, Figure 4).
During exercise, semm IGFBP-1 significantly increased with the peak value
attained at 90 minutes in all trials (p = 0.01). There was no significant difference in
IGFBP -1 between trials.
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Figure 4. IGFBP3 response to 72 (t2) hours of transdermal estradiol supplementation.
IGFBP3 significantly decreased following 72 hours of estradiol supplementation (p <
.05). Data expressed as means ± SEM.
Table 2 Baseline Serum Insulin, Glucose and Free Fatty Acid (FFA)
Concentrations in Response to Transdermal Estradiol Supplementation {N = 6)
Trial Insulin (pmol • L"') Glucose (mml • L"') FFA (mm • L"')
tl
t2
t3
28.13 ± 0.04
21.95 ±4.11
24.11 ± 6.02
3.89 ± 0.37
3.76 + 0.28
3.82 + 0.32
0.28 + 0.16
0.41 ± 0.27*
0.40 ± 0.27*
Note. Variables are expressed as mean + SE. tl = 72 hours placebo, t2 = 72 hours treatment
with transdermal estradiol, t3= 144 hours treatment with transdermal estradiol. * p < .Q5
comparison to t l .
METABOLIC SUBSTRATES
Baseline semm free fatty acids significantly increased from tl , compared to t2,
and t3 (overall p = 0.03). BaseUne semm insulin and glucose concentrations were
not significantly different between trials and were within the reported normal ranges
for these assays (Table 2).
PHYSIOLOGIC PARAMETERS
There were no significant differences in heart rate, VO ,̂ RER (Table 3), or dietary
intake between the exercise trials.
152 ± 15
148 ± 13
150 ± 16
29.49 ± 3.33
29.28 ± 3.01
28.77 + 3.46
0.92
0.91
0.90
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Table 3 Heart Rate, VO^ and RER During the Endurance Exercise Trials
Trial Heart rate (bpm) VO (ml • kg"' • min"') RER
tl
t2
t3
Note. Variables are expressed as mean ± SD. tl=72 hours placebo, t2= 72 hours treatment
with transdermal estradiol, t3= 144 hours treatment with transdermal estradiol. bpm = beats
per minute, RER=respiratory exchange ratio. There were no significant differences between
the trials for heart rate, VO^or RER.
Discussion
In the present study, we examined the effects of short-term estradiol replacement
on the GH/IGF-1 axis in a group of weight-stable young women with amenorrhea
due to exercise. To our knowledge, the present report is the first study of transdermal
estradiol effects on the GH/IGF-1 axis in this specific cohort of females with amen-
orrhea.
Three principal findings emerged from this study. First, administration of
transdermal estradiol significantly increased baseUne semm free fatty acid con-
centrations and modestly decreased semm IGFBP-3 levels. Second, transdermal
estradiol replacement had no effect on baseUne or exercise-stimulated semm GH
concentrations.
Third, prior to estradiol supplementation, exercise significantly increased
semm levels of GH, IGTOP-l, and estradiol, but transdermal estradiol did not
change exercise- stimulated responses of these hormones.
BASELINE HORMONES - PRE AND POST ESTRADIOL SUPPLEMENTATION
In our investigation, administration of transdermal estrogen produced physiologi-
cal concentrations of estradiol that infiuenced several biological endpoints. This
included increased baseUne levels of free fatty acids, and decreased semm levels
of IGFBP-3 with no effect on baseline semm GH, IGFBP-1, insulin or glucose.
The estrogen-dependent increase in baseUne FFA contrasts with previously
reported estradiol effects in postmenopausal females, in whom transdermal estra-
diol was observed to decrease FFA levels (Bhathena et al., 1998; O'SuUivan et al.,
1998).
However, there are two potential explanations for this result. It has been
reported that the basal rates of triglyceride breakdown, fatty acid release into plasma,
fatty acid oxidation, and triglyceride-fatty acid substrate cycling are two-to four-
fold higher in endurance trained male athletes compared to untrained males (Romijn
et al., 1993). The authors postulated that the increase in Upid kinetics was due to an
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increased rate of triglyceride-fatty aeid substrate cycling in the resting state, and
also increased sensitivity of adipose tissue lipolysis to hormonal control. (Romijn
et al.,1993). They excluded inadequate calorie or carbohydrate intake, and/or de-
pleted glycogen stores as potential factors in their investigation. In the present
study, we also controlled for differences in dietary intake utilizing a 72 hour di-
etary recall prior to each exercise trial, and standardized meals during the over-
night hospital admissions. We found no significant differences in total calories or
caloric content and are confident that dietary factors did not infiuence our results.
However, the proposed mechanism of increased adipose tissue Upolysis sensitiv-
ity to hormonal control is considered below (Romijn et al., 1993).
In adipose tissue, 17-beta-estradiol has a direct effect on Upoprotein Upase
and hormone-sensitive Upase; whereas in the Uver it regulates the rate of synthesis
of apolipoproteins (Szafran and Stnielak-Koromkel, 1998). Lipoprotein lipase is
involved with clearing thglyceride-rich chylomicrons and very-low-density Upo-
protein particles from the blood stream, providing free fatty acids to adipose tissue
and skeletal muscle. Hormone sensitive lipase mediates the lipolysis of
triacylglycerol resulting in the release of non-esterified fatty acids and glycerol
(Slavin et al., 1994). The hormone 17-beta-estradiol also has indirect actions on
adipose tissue by stimulating the release of catecholamines, growth hormone, and
glucagon resulting in increased hormone sensitive Upase activity (Szafran and
Smielak-Koromkel, 1998). Although we did not report any increase in basal or
exercise growth hormone concentrations in this study, we previously reported in-
creases in resting epinephrine, and norepinephrine concentrations during
transdermal estradiol supplementation in amenorrheic athletes (Ruby et al., 1997).
Due to thier small sample size and intra-subject variabiUty in epinephrine and
norepinephrine, these hormonal measures failed to reach statistical significance
(Epinephrine: 0.17 ± 0.09 vs 0.24 ± 0.13 nmol • L and Norepinephrine: 3.01 + 1.2
vs. 3.2 ± 1.1 nmol • L, respectively). It is noteworthy however, that norepinephrine
concentrations, in particular, were greater than the reported nonnai range of 0.7-
2.4 nmol • L. Norepinephrine interacts with beta-adrenergic receptors activating
adenylyl cylase, which forms cAMP. The cAMP activates protein kinase A, which
activates hormone sensitive Upase (Bray, 1992). Thus, it is conceivable that the
increase in our resting (fasting) FFA during transdermal 17-beta-estradiol therapy
may have been secondary to indirect catecholamine effects of 17-beta-estradiol on
lipid metaboUsm and endurance training effects on adipose tissue sensitivity to
hormones. These relationships, and also the potential for a synergistic effect be-
tween 17-beta-estradiol and endurance training effects on Upid metaboUsm in
amenorrheic female athletes warrant further investigation.
SERUM ESTRADIOL, GH AND IGFBP-1 DURING EXERCISE
PRE AND POST ESTRADIOL SUPPLEMENTATION
Estradiol. The increase in estradiol levels observed during all exercise trials could
be related to several factors including increased ovarian production of estradiol,
increased cutaneous blood fiow leading to augmented absorption from the estra-
diol patch, or delayed clearance of estradiol. We favor the concept of delayed clear-
ance, because if one looks at Figure 2, it is apparent that the estradiol delta in tl
compared to t2 and t3 are almost identical. Furthermore, a previous study also
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demonstrated that the exercise-induced shunting of blood fiow away from the Uver
leads to an increase in the half-Ufe and semm level of estradiol, thus favoring the
premise of decreased clearance (Chen and Brzyski, 1999).
GH. Exercise is a stimulus for GH secretion, and therefore the rise in GH con-
centrations associated with exercise as shown in Figure 3 were expected. The ap-
parent blunting of the semm GH response during exercise at t2 was related to a
delay in the GH peaks in two subjects. A similar effect of transdermal estradiol on
the timing of the GH peak in post-menopausal females has also been reported
(Cano et al., 1999), although the lack of this effect at t3 in our study indicates that
this was most likely an anomaly of that trial.
Estradiol administration had no effect on baseline or peak exercise-stimu-
lated GH concentrations. The lack of an estrogen effect on basal or stimulated GH
levels in spite of significantly increased baseUne E2 levels in amenonheic athletes
may be related to either the duration of estrogen replacement or to the estradiol
dose (Bellantoni et al., 1996; Friend et al., 1996; Goodman-Gmen and Barrett-
Conner, 1996). Previous studies in postmenopausal women and in women with
hypothalamic amenorrhea associated with weight- loss, have reported that
transdermal estradiol administration increased noctumal, integrated GH AUC, and
spontaneous episodic GH release (Friend et al., 1996; Genazzani et al., 1993,1998).
Conversely, transdermal estradiol in postmenopausal females has been reported to
not alter noctumal GH secretion, or morning IGF-1, but decrease IGFBP-3
(Bellantoni et al., 1996). These disparate findings raise the question of underlying
physiological differences in the amenorrhea of menopause, hypothalamic amenor-
rhea due to weight-loss, and amenorrhea secondary to exercise in weight-stable
athletes.
IGF-1. Our semm IGF-1 findings are in agreement with a report of no change in
IGF-1 during short-term estradiol supplementation in postmenopausal females
(Bellantoni et al., 1996), and are in contrast to other reports of increased IGF-1
with transdermal estradiol (Genazzani et al., 1998; Weissberger et al., 1991). The
report of increased IGF-1 with transdermal estradiol included both hypogonado-
tropic and normogonadotrophic weightloss-associated amenorrheics and concluded
that the hormonal abnormalities in amenorrhea related to weight loss were only
partially dependent on the hypoestrogenic condition. Others have also postulated
that the inabiUty to fully restore the GH/IGF-1 axis with estradiol supplementation
may be dependent on an intact ovarian-pituitary feedback system (Weissberger et
al., 1991). However, in our previous study, normal-weight amenorrheic athletes
demonstrated elevated GH concentrations between pulses, and dismpted noctur-
nal semm GH secretion, but no differences in semm IGF-1 compared to closely
matched eumenorrheic athletes, both of whom presumably had an intact ovarian-
pituitary feedback (Waters et al., 2001). Furthermore, during exercise the normal
relationship between IGF-1 and GH was completely reversed in the amenorrheic
females. This uncoupUng of E2 regulation ofthe GH/IGF-1 axis has been reported
in aging female primates (Wilson, 1998). If the amenorrheic females in our current
investigation had dismpted noctumal GH secretory kinetics as reported by our-
selves and other investigators (LaughUn et al., 1998; Waters et al., 2001; Yen and
Laughlin, 1996), this might account for an uncoupUng between the normal rela-
tionship of E2 and the GH/IGF-1 axis.
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IGFBP-1. The mechanism for exercise-induced increase in IGFBP-1 has been
reported in several studies and is likely due to decreases in insulin during pro-
longed exercise (Cano et al., 1999; Jenkins et al., 1993; Lee et al., 1993). In our
study, exercise significantly increased IGFBP-1 levels, but there was no difference
in exercise-stimulated IGFBP-1 during transdermal estradiol supplementation.
AdditionaUy, neither baseUne nor exercise-stimulated IGFBP-1 was affected by
increasing estradiol concentrations. This lack of an IGFBP-1 response to estradiol
is somewhat surprising, since sex steroids have been reported to negatively regu-
late IGFBP-1 (Cano etal., 1999; Prange-Hansen and Weeke, 1974), and transdermal
estradiol apparently decreases IGFBP-1 (Cano et al., 1999; Jenkins et al., 1993;
Lee et al., 1993). However, baseUne IGFBP-1 concentrations in our amenorrheic
athletes in this investigation were not elevated as reported by others (Jenkins et al.,
1993), nor did we find a relationship between menstmal status and IGFBP-1 in our
previous study of eumenorrheic and amenorrheic athletes with comparable estra-
diol concentrations (Waters et al., 2001). Therefore, the unresponsiveness of IGFBP-
1 to increasing semm estradiol levels may be due to the short duration of therapy
or final semm concentrations of estradiol attained.
Limitations and Conclusion
The present study focuses on a unique cohort of women with athletic amenorrhea
from which women athletes with severe eating disorders were excluded. The se-
lection of this group of females with a specific etiology of amenorrhea is impor-
tant for excluding the potential contributions of severe nutritional deficiencies and
metaboUc alterations on the activity ofthe GH/IGF-1 axis. However, several limi-
tations to our findings should be discussed.
Although the differences we report in IGBP-3 appear small, another investi-
gation also reported a similar small decrease in postmenopausal females (Bellantoni
et cd., 1996). We conducted a post-hoc power analysis of our main hypothesis that
IGFBP-3 will decrease with transdermal estrogen therapy, and used the observed
standard deviation for the (t2 vs tl) differences in IGFBP-3 level of 0.25 (xg/L.
Using this, our sample size of n = 7 was adequate to detect a 0.32 ng/L difference
with 80% power and a = 0.05. However, the physiological relevance of this find-
ing is unclear, as the normal range for IGFBP-3 in adult females is 2.0-4.9 |xg •
L"', and the 6% change we reported, was still in the normal range. Thus, the physi-
ological consequence of this finding is most likely insignificant.
We also recognize that this study was not well powered for TVpe-II errors. A
post-hoc power analysis for changes in IGF-1 based on the observed standard de-
viation of these changes (tl vs t2) of 23.2 (xg/L revealed that our sample size of n
= 7 was adequate to detect a 30 jJig/L difference with 80% power and a = 0.05.
This change is approximately a 10% difference from baseline IGF-1 levels. Note
that the within-subject standard deviation of 23.2 is much less than the between-
subject standard deviation of 88, which indicates the difficulty in intra-subject
variabiUty in hormonal concentrations.
Finally, it will be important to assess whether the observed discrepancies we
report fi'om this study are due to differences in the dose or duration of transdermal
estradiol replacement or refiect important biological differences in the GH/IGF-
laxis in the etiology of athletic amenorrhea. Although the transdermal estradiol
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patch brought estradiol levels into a mid-follicular range, the short duration of the
therapy limits the interpretation of our results. Further studies are needed utiUzing
a 6-12 week course of therapy, varying doses, and with the inclusion of eumenorrheic
controls to make this cohort study comparable to amenorrhea of different etiolo-
gies.
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